News

TB R&D Update: Semisynthetic antibiotic effective against sensitive and drug resistant tuberculosis in vitro

Richard E. Lee et al. Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux. Nature Medicine. 2014. March 6; 20(152). doi:10.1038/nm.3458

Abstract:

Although the classical antibiotic spectinomycin is a potent bacterial protein synthesis inhibitor, poor antimycobacterial activity limits its clinical application for treating tuberculosis. Using structure-based design, we generated a new semisynthetic series of spectinomycin analogs with selective ribosomal inhibition and excellent narrow-spectrum antitubercular activity. In multiple murine infection models, these spectinamides were well tolerated, significantly reduced lung mycobacterial burden and increased survival. In vitro studies demonstrated a lack of cross resistance with existing tuberculosis therapeutics, activity against multidrug-resistant (MDR) and extensively drug-resistant tuberculosis and an excellent pharmacological profile. Key to their potent antitubercular properties was their structural modification to evade the Rv1258c efflux pump, which is upregulated in MDR strains and is implicated in macrophage-induced drug tolerance. The antitubercular efficacy of spectinamides demonstrates that synthetic modifications to classical antibiotics can overcome the challenge of intrinsic efflux pump-mediated resistance and expands opportunities for target-based tuberculosis drug discovery.

Additional Coverage:

New antibiotic could overcome drug-resistant TB

Treating tuberculosis with spectinamides

Spectinamides: New class of mutant drugs makes progress against TB

Drug-resistant tuberculosis: a new shot on goal

New hope against tuberculosis: spectinamides

Additional TB R&D Updates:

Antibody-Free Detection of Mycobacterium tuberculosis Antigen Using Customized Nanotraps

Treating Tuberculosis and AIDS Together Saves Lives

Acetic Acid, the Active Component of Vinegar, Is an Effective Tuberculocidal Disinfectant

CAfGEN receives $3 million grant to study progression of TB and HIV

Chemist gets US patent for solution to resistance problem

More News
22 Jul 2024
The National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) has issued a $30.8 million grant to the Preclinical Design and Clinical Translation of TB Regimens (PreDiCTR) consortium , a new consortium co-led by investigators from Weill Cornell Medicine; the...
27 Jun 2024
On May 17, the World Health Organization (WHO) released its updated  Bacterial Priority Pathogens List (BPPL) 2024 and for the first time in its history it included a drug resistant strain of Mycobacterium tuberculosis. Along with three other new families of antibiotic-resistant bacterial pathogens...
19 Mar 2024
For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...